Colon primary cancer with metastatic
To Order Contact us: lieven@wlsolutions.be
Lung cancer tissue array with matched metastatic lymph node |
||
LC814a | each | EUR 306 |
Description: Lung cancer tissue array with matched metastatic lymph node, 40 cases/80 cores, replacing LC814 |
Lung cancer with matched lymph node metastatic carcinoma tissue array |
||
LC817b | each | EUR 258 |
Description: Lung cancer with matched lymph node metastatic carcinoma tissue array, including pathology grade, TNM and clinical stage, 40 cases/80 cores, replacing LC817a |
Breast cancer with matched metastatic carcinoma or breast tissue array |
||
BRM961a | each | EUR 384 |
Description: Breast cancer with matched metastatic carcinoma or breast tissue array, including pathology grade, TNM, clinical stage and IHC marker (ER, PR and Her-2), 49 cases/96 cores |
Lung cancer tissue array with matched metastatic carcinoma and cancer adjacent tissue |
||
LC953 | each | EUR 1434 |
Description: Lung cancer tissue array with matched metastatic carcinoma and cancer adjacent tissue, including TNM, clinical stage, pathology grade and survival data, 30 cases/95 cores, replacing LC952 |
Colorectal cancer tissue array with matched normal adjacent and metastatic carcinoma tissue |
||
CO952a | each | EUR 1434 |
Description: Colorectal cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and survival data, 30 cases/95 cores. |
Breast cancer with matched metastatic carcinoma of lymph node tissue array |
||
BR1005b | each | EUR 306 |
Description: Breast cancer with matched metastatic carcinoma of lymph node tissue array, including pathology grade, TNM and clinical stage, 50 cases/100 cores, replacing BR1005a |
Cervix cancer and normal tissue array with CIN and metastatic carcinoma |
||
CR208 | each | EUR 546 |
Description: Cervix cancer and normal tissue array with CIN and metastatic carcinoma, including pathology grade, TNM and clinical stage, 69 cases/207 cores |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) |
||
MBS4380553-002mgWithBSAAzideat02mgmL | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) |
||
MBS4380553-01mgWithBSAAzideat02mgmL | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) |
||
MBS4380553-01mgWithoutBSAAzideat1mgmL | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) |
||
MBS4380553-5x01mgWithBSAAzideat02mgmL | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) |
||
MBS4380553-5x01mgWithoutBSAAzideat1mgmL | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer) |
||
MBS4380892-002mgWithBSAAzideat02mgmL | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer) |
||
MBS4380892-01mgWithBSAAzideat02mgmL | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer) |
||
MBS4380892-01mgWithoutBSAAzideat1mgmL | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer) |
||
MBS4380892-5x01mgWithBSAAzideat02mgmL | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer) |
||
MBS4380892-5x01mgWithoutBSAAzideat1mgmL | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) |
||
MBS4380894-002mgWithBSAAzideat02mgmL | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) |
||
MBS4380894-01mgWithBSAAzideat02mgmL | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) |
||
MBS4380894-01mgWithoutBSAAzideat1mgmL | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) |
||
MBS4380894-5x01mgWithBSAAzideat02mgmL | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) |
||
MBS4380894-5x01mgWithoutBSAAzideat1mgmL | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
Liver metastatic cancer tissue array |
||
MLV801 | each | EUR 354 |
Description: Liver metastatic cancer tissue array, including pathology grade, TNM and clinical stage, 80 cases/80 cores |
Metastatic esophageal cancer tissue array |
||
ES806 | each | EUR 306 |
Description: Metastatic esophageal cancer tissue array, 40 cases/80 cores |
Kidney cancer tissue array with matched normal adjacent tissue and metastatic carcinoma |
||
KD951a | each | EUR 1434 |
Description: Kidney cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage, pathology grade and survival data, 32 cases/95 cores,replacing KD951 |
Multiple organ metastatic cancer tissue array |
||
MT2081 | each | EUR 474 |
Description: Multiple organ metastatic cancer tissue array, 19 organ/104 cases/208 cores |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(FABP5/3750), 1mg/mL |
||
BNUM3750-50 | 1uL | EUR 396 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(FABP5/3750), 0.2mg/mL |
||
BNUB3750-100 | 1uL | EUR 225 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(FABP5/3750), 0.2mg/mL |
||
BNUB3750-500 | 1uL | EUR 485 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
Cancer Antigen CEA Antigen (Human Metastatic Liver) |
||
VAng-Wyb8645-inquire | inquire | Ask for price |
Description: Carcinoembryonic Antigen, Antigen Grade, Cancer antigen from Human Metastatic Liver, 5.5 mg/mL. |
Matched Pair - DNA - Human Primary and Metastatic Tumor Tissue: Lung |
||
D8235152-PM-10 | 2x10 ug | EUR 555.8 |
Matched Pair - DNA - Human Primary and Metastatic Tumor Tissue: Liver |
||
D8235149-PM-10 | 2x10 ug | EUR 555.8 |
Matched Pair - DNA - Human Primary and Metastatic Tumor Tissue: Breast |
||
D8235086-PM-10 | 2x10 ug | EUR 555.8 |
Matched Pair - DNA - Human Primary and Metastatic Tumor Tissue: Kidney |
||
D8235142-PM-10 | 2x10 ug | EUR 555.8 |
Matched Pair - DNA - Human Primary and Metastatic Tumor Tissue: Rectum |
||
D8235206-PM-10 | 2x10 ug | EUR 555.8 |
Matched Pair - DNA - Human Primary and Metastatic Tumor Tissue: Stomach |
||
D8235248-PM-10 | 2x10 ug | EUR 555.8 |
Malignant melanoma and metastatic malignant melanoma TMA with 6 matched cancer adjacent tissue samples |
||
ME551 | each | EUR 270 |
Description: Malignant melanoma and metastatic malignant melanoma TMA with 6 matched cancer adjacent tissue samples, including TNM and clinical stage (reference AJCC th version), 49cases/55 cores (core size 1.5mm) Recent Year Collection |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP5-3), 1mg/mL |
||
BNUM2225-50 | 1uL | EUR 396 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP2-3), 1mg/mL |
||
BNUM2226-50 | 1uL | EUR 396 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP5-3), 0.2mg/mL |
||
BNUB2225-100 | 1uL | EUR 225 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP5-3), 0.2mg/mL |
||
BNUB2225-500 | 1uL | EUR 485 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP2-3), 0.2mg/mL |
||
BNUB2226-100 | 1uL | EUR 225 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP2-3), 0.2mg/mL |
||
BNUB2226-500 | 1uL | EUR 485 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
Breast cancer and matched metastatic carcinoma tissue array |
||
BR10010f | each | EUR 354 |
Description: Breast cancer and matched metastatic carcinoma tissue array, including TNM and pathology grade,IHC (ER,PR,Her-2,Ki67) markers results, 50 cases/100 cores, replacing BR10010e |
Breast cancer and matched metastatic carcinoma tissue array |
||
BR20837a | each | EUR 546 |
Description: Breast cancer and matched metastatic carcinoma tissue array, including TNM, clinical stage and pathology grade, 104 cases/ 208 cores, replacing BR20837 |
Matched Pair - cDNA - Human Primary and Matched Metastatic Tumor Tissue: Liver |
||
C8235149-PM | 10 reactions x2 | EUR 848.4 |
Matched Pair - cDNA - Human Primary and Matched Metastatic Tumor Tissue: Lung |
||
C8235152-PM | 10 reactions x2 | EUR 848.4 |
Cancer of the cervix paired with metastatic tumors in lymph nodes, 12 cases (1.5mm)HumanReproductive systemCervixMalignant |
||
CXM481 | 1 | EUR 289 |
Matched Pair - cDNA - Human Primary and Matched Metastatic Tumor Tissue: Breast |
||
C8235086-PM | 10 reactions x2 | EUR 848.4 |
Matched Pair - cDNA - Human Primary and Matched Metastatic Tumor Tissue: Kidney |
||
C8235142-PM | 10 reactions x2 | EUR 848.4 |
Matched Pair - cDNA - Human Primary and Matched Metastatic Tumor Tissue: Rectum |
||
C8235206-PM | 10 reactions x2 | EUR 848.4 |
Matched Pair - cDNA - Human Primary and Matched Metastatic Tumor Tissue: Stomach |
||
C8235248-PM | 10 reactions x2 | EUR 848.4 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(FABP5/3750), CF488A conjugate, 0.1mg/mL |
||
BNC883750-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(FABP5/3750), CF488A conjugate, 0.1mg/mL |
||
BNC883750-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(FABP5/3750), Biotin conjugate, 0.1mg/mL |
||
BNCB3750-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(FABP5/3750), Biotin conjugate, 0.1mg/mL |
||
BNCB3750-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(FABP5/3750), CF594 conjugate, 0.1mg/mL |
||
BNC943750-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(FABP5/3750), CF594 conjugate, 0.1mg/mL |
||
BNC943750-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(FABP5/3750), CF640R conjugate, 0.1mg/mL |
||
BNC403750-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(FABP5/3750), CF640R conjugate, 0.1mg/mL |
||
BNC403750-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(FABP5/3750), CF647 conjugate, 0.1mg/mL |
||
BNC473750-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(FABP5/3750), CF647 conjugate, 0.1mg/mL |
||
BNC473750-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(FABP5/3750), CF405S conjugate, 0.1mg/mL |
||
BNC043750-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(FABP5/3750), CF405S conjugate, 0.1mg/mL |
||
BNC043750-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(FABP5/3750), CF568 conjugate, 0.1mg/mL |
||
BNC683750-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(FABP5/3750), CF568 conjugate, 0.1mg/mL |
||
BNC683750-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
Cancer Antigen CA 19-9 Antigen (Human metastatic liver carcinoma) |
||
VAng-Wyb8635-inquire | inquire | Ask for price |
Description: CA 19-9 (Gastrointestinal Cancer), Antigen Grade, Cancer antigen from Human metastatic liver carcinoma, 2900.0 kIU/mL. |
Metastatic Tumor Tissue Array - 18 cases of metastatic cancers from 4 anatomic sites |
||
Z7020073 | 5 slides | EUR 1125.6 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Metastatic Tumor Tissue Array - 48 cases of metastatic cancers from 8 anatomic sites |
||
Z7020074 | 5 slides | EUR 1657.2 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Cancer of the colon paired with metastasis, 48 cases (1.5mm)HumanDigestive systemColonMalignant, metastasis |
||
COM961 | 1 | EUR 448 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP5-3), CF594 conjugate, 0.1mg/mL |
||
BNC942225-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP5-3), CF594 conjugate, 0.1mg/mL |
||
BNC942225-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP2-3), CF594 conjugate, 0.1mg/mL |
||
BNC942226-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP2-3), CF594 conjugate, 0.1mg/mL |
||
BNC942226-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP5-3), CF647 conjugate, 0.1mg/mL |
||
BNC472225-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP5-3), CF647 conjugate, 0.1mg/mL |
||
BNC472225-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP2-3), CF647 conjugate, 0.1mg/mL |
||
BNC472226-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP2-3), CF647 conjugate, 0.1mg/mL |
||
BNC472226-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP5-3), CF568 conjugate, 0.1mg/mL |
||
BNC682225-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP5-3), CF568 conjugate, 0.1mg/mL |
||
BNC682225-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP2-3), CF568 conjugate, 0.1mg/mL |
||
BNC682226-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP2-3), CF568 conjugate, 0.1mg/mL |
||
BNC682226-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
Multiple bladder cancer with bladder tissue array, with metastatic carcinoma, including pathology grade, TNM and clinical satge, 64 cases/192 cores, replacing BL208 |
||
UBD208a | row: 12; column: 16; cores: 192; cases: 64 | EUR 546 |
Description: Multiple bladder carcinoma with bladder tissue microarray, containing 38 cases of urothelial carcinoma, 6 squamous cell carcinoma, 7 adenocarcinoma, 4 metastatic urothelial carcinoma, 9 bladder tissue, triplicated cores per case |
Breast cancer and breast tissue array, with metastatic carcinoma, including pathology grade, TNM and clinical stage, 96 cases/100 cores |
||
FMG1001 | row: 10; column: 10; cores: 100; cases: 96 | EUR 258 |
Description: Breast cancer and breast tissue microarray, contaning 44 cases of invasive carcinoma of no special type, 5 medullary carcinoma, 1 neuroendocrine carcinoma, 37 metastatic invasive carcinoma of no special type, 2 metastatic lobular carcinoma, 1 metastatic medullary carcinoma, 3 breast tissue, 7 adjacent normal breast tissue, single core per block |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP5-3), Biotin conjugate, 0.1mg/mL |
||
BNCB2225-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP5-3), Biotin conjugate, 0.1mg/mL |
||
BNCB2225-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP2-3), Biotin conjugate, 0.1mg/mL |
||
BNCB2226-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP2-3), Biotin conjugate, 0.1mg/mL |
||
BNCB2226-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP5-3), CF488A conjugate, 0.1mg/mL |
||
BNC882225-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP5-3), CF488A conjugate, 0.1mg/mL |
||
BNC882225-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP2-3), CF488A conjugate, 0.1mg/mL |
||
BNC882226-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP2-3), CF488A conjugate, 0.1mg/mL |
||
BNC882226-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP5-3), CF640R conjugate, 0.1mg/mL |
||
BNC402225-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP5-3), CF640R conjugate, 0.1mg/mL |
||
BNC402225-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP2-3), CF640R conjugate, 0.1mg/mL |
||
BNC402226-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP2-3), CF640R conjugate, 0.1mg/mL |
||
BNC402226-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP5-3), CF405S conjugate, 0.1mg/mL |
||
BNC042225-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP5-3), CF405S conjugate, 0.1mg/mL |
||
BNC042225-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP2-3), CF405S conjugate, 0.1mg/mL |
||
BNC042226-100 | 1uL | EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FABP2 (Marker of Metastatic Potential in Colorectal Cancer)(CPTC-FABP2-3), CF405S conjugate, 0.1mg/mL |
||
BNC042226-500 | 1uL | EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
Colon adenocarcinoma and metastatic adenocarcinoma tissue array |
||
CO953a | each | EUR 1434 |
Description: Colon adenocarcinoma and metastatic adenocarcinoma tissue array, with matched colon tissue, including survival data, pathology grade, TNM and clinical stage, 39 cases/96 cores, replacing CO953 |
PC-3 Human prostate cancer cells derived from metastatic cancer cell line: >1x10^10 frozen exosomes |
||
EXOP-115A-1 | 50 ug | EUR 409 |
Human Metastasis Associated In Colon Cancer 1 (MACC1) Antibody Pair Kit (with Standard) |
||
MBS2104415-10x96Tests | 10x96Tests | EUR 1615 |
Human Metastasis Associated In Colon Cancer 1 (MACC1) Antibody Pair Kit (with Standard) |
||
MBS2104415-10x96TestsMBS2090685AbPairsSupportPack110x96Tests | 10x96Tests+MBS2090685(AbPairsSupportPack1,10x96Tests) | EUR 1735 |
Human Metastasis Associated In Colon Cancer 1 (MACC1) Antibody Pair Kit (with Standard) |
||
MBS2104415-5x96Tests | 5x96Tests | EUR 1020 |
Human Metastasis Associated In Colon Cancer 1 (MACC1) Antibody Pair Kit (with Standard) |
||
MBS2104415-5x96TestsMBS2090685AbPairsSupportPack15x96Tests | 5x96Tests+MBS2090685(AbPairsSupportPack1,5x96Tests) | EUR 1090 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) Recombinant Mouse Monoclonal Antibody [Clone rFABP5/6354] |
||
MBS4381879-002mgWithBSAAzideat02mgmL | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) Recombinant Mouse Monoclonal Antibody [Clone rFABP5/6354] |
||
MBS4381879-01mgWithBSAAzideat02mgmL | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) Recombinant Mouse Monoclonal Antibody [Clone rFABP5/6354] |
||
MBS4381879-01mgWithoutBSAAzideat1mgmL | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) Recombinant Mouse Monoclonal Antibody [Clone rFABP5/6354] |
||
MBS4381879-5x01mgWithBSAAzideat02mgmL | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) Recombinant Mouse Monoclonal Antibody [Clone rFABP5/6354] |
||
MBS4381879-5x01mgWithoutBSAAzideat1mgmL | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) Recombinant Rabbit Monoclonal Antibody [Clone FABP5/6353R] |
||
MBS4381880-002mgWithBSAAzideat02mgmL | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) Recombinant Rabbit Monoclonal Antibody [Clone FABP5/6353R] |
||
MBS4381880-01mgWithBSAAzideat02mgmL | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) Recombinant Rabbit Monoclonal Antibody [Clone FABP5/6353R] |
||
MBS4381880-01mgWithoutBSAAzideat1mgmL | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) Recombinant Rabbit Monoclonal Antibody [Clone FABP5/6353R] |
||
MBS4381880-5x01mgWithBSAAzideat02mgmL | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
FABP5 (Marker of Metastatic Potential in Colorectal Cancer) Recombinant Rabbit Monoclonal Antibody [Clone FABP5/6353R] |
||
MBS4381880-5x01mgWithoutBSAAzideat1mgmL | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
Colon cancer with colon tissue array |
||
CO1021a | each | EUR 306 |
Description: Colon cancer with colon tissue array, including pathology grade, with MMR (MLH1/PMS2/MSH2/MSH6) IHC results,TNM and clinical stage, containing 86 cases of adenocarcinoma, 4 papillary adenocarcinoma, 7 mucinous adenocarcinoma, 2 adenoma, 1 congenital megacolon, 2 colon tissue, 102 cases/102 cores replacing CO1021 |
Colon cancer with colon tissue array |
||
CO1921 | each | EUR 546 |
Description: Colon cancer with colon tissue array, including pathology grade, TNM and clinical stage, 192 cases/192 cores |
Colon cancer with colon tissue array |
||
CO2161b | each | EUR 474 |
Description: Colon cancer with colon tissue array, including pathology grade, TNM and clinical stage, 216 cases/216 cores, replacing CO2161a |
Colon cancer with colon tissue array |
||
CO721 | each | EUR 270 |
Description: Colon cancer with colon tissue array, including pathology grade, TNM and clinical stage, 24 cases/72 cores |
Colon cancer with colon tissue array |
||
CO805 | each | EUR 258 |
Description: Colon cancer with colon tissue array, including pathology grade, TNM and clinical stage, 40 cases/80 cores |
Metastasis-associated in colon cancer protein 1 |
||
AP84814 | 1mg | EUR 2640 |
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
abx132298-100tests | 100 tests | EUR 300 |
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
20-abx132298 |
|
|
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
abx104134-100g | 100 µg | EUR 825 |
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
20-abx104134 |
|
|
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
abx104134-20g | 20 µg | EUR 287.5 |
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
abx104134-50g | 50 µg | EUR 362.5 |
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
20-abx121640 |
|
|
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
abx234920-100g | 100 µg | EUR 350 |
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
abx234920-100ug | 100 ug | EUR 610.8 |
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
abx325504-100g | 100 µg | EUR 250 |
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
20-abx325504 |
|
|
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
abx325504-50g | 50 µg | EUR 187.5 |
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
20-abx242861 |
|
|
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
abx242861-96tests | 96 tests | EUR 612.5 |
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
abx210666-100l | 100 µl | EUR 350 |
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
20-abx210666 |
|
|
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
abx210666-50l | 50 µl | EUR 250 |
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
abx210667-100l | 100 µl | EUR 350 |
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
20-abx210667 |
|
|
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
abx210667-50l | 50 µl | EUR 250 |
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
abx375246-96tests | 96 tests | EUR 337.5 |
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
abx338434-100g | 100 µg | EUR 162.5 |
Metastasis Associated In Colon Cancer 1 (MACC1) Antibody |
||
20-abx338434 |
|
|
Rat Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS097090-10x96StripWells | 10x96-Strip-Wells | EUR 6725 |
Rat Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS097090-48StripWells | 48-Strip-Wells | EUR 550 |
Rat Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS097090-5x96StripWells | 5x96-Strip-Wells | EUR 3420 |
Rat Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS097090-96StripWells | 96-Strip-Wells | EUR 765 |
Cat Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS068902-INQUIRE | INQUIRE | Ask for price |
Fish Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS095307-INQUIRE | INQUIRE | Ask for price |
Cavy Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS080232-INQUIRE | INQUIRE | Ask for price |
Goat Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS053444-INQUIRE | INQUIRE | Ask for price |
Duck Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS054027-INQUIRE | INQUIRE | Ask for price |
MDA-MB-231 Human breast cancer, aggressive/invasive/metastatic cell line: >1x10^10 frozen exosomes |
||
EXOP-105A-1 | 50 ug | EUR 409 |
Colon cancer with matched colon tissue array |
||
CO1801a | each | EUR 474 |
Description: Colon cancer with matched colon tissue array, including pathology grade,with MMR (MLH1/PMS2/MSH2/MSH6) IHC results, TNM and clinical stage, containing 90 cases of adenocarcinoma, and 90 cancer adjacent or adjacent normal colon tissue, 90 cases/180 cores, replacing CO1801 |
Colon cancer with matched colon tissue array |
||
CO602a | each | EUR 222 |
Description: Colon cancer with matched colon tissue array, including pathology grade, TNM and clinical stage, 30 cases/60 cores, replacing CO602 |
Colon cancer with matched colon tissue array |
||
CO703 | each | EUR 198 |
Description: Colon cancer with matched colon tissue array, including pathology grade, TNM and clinical stage, 35 cases/70 cores,replaced by CO703a |
Human Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS108228-10x96StripWells | 10x96-Strip-Wells | EUR 6725 |
Human Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS108228-48StripWells | 48-Strip-Wells | EUR 550 |
Human Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS108228-5x96StripWells | 5x96-Strip-Wells | EUR 3420 |
Human Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS108228-96StripWells | 96-Strip-Wells | EUR 765 |
Mouse Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS088621-10x96StripWells | 10x96-Strip-Wells | EUR 6725 |
Mouse Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS088621-48StripWells | 48-Strip-Wells | EUR 550 |
Mouse Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS088621-5x96StripWells | 5x96-Strip-Wells | EUR 3420 |
Mouse Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS088621-96StripWells | 96-Strip-Wells | EUR 765 |
Goose Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS097938-INQUIRE | INQUIRE | Ask for price |
Camel Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS072580-10x96StripWells | 10x96-Strip-Wells | EUR 6725 |
Camel Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS072580-48StripWells | 48-Strip-Wells | EUR 550 |
Camel Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS072580-5x96StripWells | 5x96-Strip-Wells | EUR 3420 |
Camel Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS072580-96StripWells | 96-Strip-Wells | EUR 765 |
Sheep Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS060908-10x96StripWells | 10x96-Strip-Wells | EUR 6725 |
Sheep Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS060908-48StripWells | 48-Strip-Wells | EUR 550 |
Sheep Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS060908-5x96StripWells | 5x96-Strip-Wells | EUR 3420 |
Sheep Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS060908-96StripWells | 96-Strip-Wells | EUR 765 |
Horse Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS061108-10x96StripWells | 10x96-Strip-Wells | EUR 6725 |
Horse Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS061108-48StripWells | 48-Strip-Wells | EUR 550 |
Horse Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS061108-5x96StripWells | 5x96-Strip-Wells | EUR 3420 |
Horse Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS061108-96StripWells | 96-Strip-Wells | EUR 765 |
Human Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
IHUMACC1KT | each | EUR 799 |
Description: Human Metastasis Associated In Colon Cancer 1 ELISA Kit |
Canine Metastasis Associated In Colon Cancer 1 ELISA Kit |
||
MBS063715-10x96StripWells | 10x96-Strip-Wells | EUR 6725 |